Skip to main content
Equibles

Christine Coyne

Iterum Therapeutics plc (ITRMF)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Christine Coyne

Scynexis Inc reported in an 8-K filed October 20, 2022 that Christine Coyne was terminated as Chief Commercial Officer, effective November 30, 2022. The proxy statement of Scynexis Inc reports total compensation of $1,164,197 for Christine Coyne in fiscal 2022, including a base salary of $369,726. Disclosed compensation is on record for 2 fiscal years.

“On October 14, 2022, SCYNEXIS informed Christine Coyne, Chief Commercial Officer of SCYNEXIS, that she will cease to be an employee and Chief Commercial Officer effective November 30, 2022.”
Scynexis Inc Form 8-K, filed October 20, 2022 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Iterum Therapeutics plc

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Scynexis Inc (SCYX) $369,726 $1,164,197
2021 Scynexis Inc (SCYX) $254,509 $1,033,194

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.